Clinical Trials Logo

Clinical Trial Summary

The purpose of the trial is to study the tolerability, safety and pharmacokinetics of the study drug with participation of healthy volunteers after single intravenous administration with dose escalation (0.03 mg/kg, 0.06 mg/kg and 0.12 mg/kg). Before administration the study drug will be dosed and diluted in 200 ml of isotonic solution of 0.9% sodium chloride, and then will be administered once intravenously via infusion. During the entire follow-up period, the effect of the study drug on vital signs, instrumental and laboratory data, the development, severity and association of adverse events with the study drug will be monitored, investigated and studied.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT06127381
Study type Interventional
Source Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation
Contact
Status Not yet recruiting
Phase Phase 1
Start date November 2023
Completion date April 2024

See also
  Status Clinical Trial Phase
Completed NCT03909854 - Pragmatic Investigation of Volume Targeted Ventilation-1 N/A
Recruiting NCT02637011 - Surviving ARDS: The Influence of Quality of Care and Individual Patient Characteristics on Quality of Life N/A
Completed NCT02288949 - Stratification of the Acute Respiratory Distress Syndrome
Recruiting NCT02574169 - Alveolar Recruitment Maneuvers, Intracerebral Hemodynamic and Oxygenation N/A
Completed NCT04548739 - Cerebral Autoregulation in Pediatric ECMO (ECMOX 2)
Completed NCT05024500 - Clinical and Functional Outcomes of Critically Ill Patients With COVID-19 N/A
Terminated NCT04511650 - Evaluation of the Safety and Efficacy of Razuprotafib in Hospitalized Subjects With Coronavirus Disease 2019 Phase 2
Recruiting NCT01339533 - Airway Pressure Release Ventilation (APRV) Versus AC/VC Conventional Ventilation Phase 2
Active, not recruiting NCT01274260 - Trial of Steroids in Pediatric Acute Lung Injury/ARDS Phase 2
Recruiting NCT03296059 - Transfusion of Red Blood Cells for Acute Respiratory Distress Syndrome(ARDS) in Neonates N/A
Recruiting NCT04609865 - Impact of Intravenous Lidocaine on Clinical Outcomes of Patients With ARDS During COVID-19 Pandemia Phase 3
Active, not recruiting NCT04009330 - Clinical Evaluation of a Point of Care (POC) Assay to Identify Phenotypes in the Acute Respiratory Distress Syndrome
Not yet recruiting NCT05847517 - Metoprolol in Acute Respiratory Distress Syndrome (MAIDEN) Phase 3
Completed NCT01854424 - Validation of the Percentage of Alveolar Fibrocyte as Biomarker During ARDS N/A
Completed NCT03870009 - Validation of a Semi-automatized Method to Detect Cyclic Hyperinflation on CT-scan in ARDS N/A
Completed NCT04311697 - Intravenous Aviptadil for Critical COVID-19 With Respiratory Failure Phase 2/Phase 3
Recruiting NCT02095444 - Using Human Menstrual Blood Cells to Treat Acute Lung Injury Caused by H7N9 Bird Flu Virus Infection Phase 1/Phase 2
Recruiting NCT04460859 - RecruitmEnt Assessed by eleCtRical Impedance Tomography
Completed NCT01926093 - Low Dose Lung CT Scan for Quantitative Analysis in ARDS Patients N/A
Terminated NCT01506401 - The Oscillation for Acute Respiratory Distress Syndrome (ARDS) Treated Early (OSCILLATE) Trial Phase 3